



Altice USA Q4 and Full Year 2021 consensus estimates for Altice USA analysts

Figures shown in USD millions

Financials - Quarterly	Q4 20 Act	Q4 21 Cons	21 Cons / 20 Act
Revenue	2,535	2,521	(0.6%)
Adj. EBITDA	1,151	1,101	(4.3%)
Capex (Cash)	345	435	26.2%
EBITDA - Capex (Cash)	806	666	(17.4%)

Financials - Annual	FY 20 Act	FY 21 Cons	21 Cons / 20 Act
Revenue	9,895	10,091	2.0%
Adj. EBITDA	4,415	4,445	0.7%
Capex (Cash)	1,074	1,280	19.2%
EBITDA - Capex (Cash)	3,341	3,166	(5.2%)

Notes:

Sell-side analyst estimates are based on the average of forecasts from 23 Altice USA analysts as of February 3, 2021.